SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, today announced the successful closing of a $90 million Series D financing round, which includes the conversion of a convertible note.

加利福尼亚州南旧金山——（商业新闻短讯）——Circle Pharma是一家临床阶段的生物制药公司，致力于发现和开发细胞渗透性大环化合物作为一种新的治疗方法，今天宣布成功完成一轮9000万美元的D系列融资，其中包括可转换票据的转换。

The financing was led by The Column Group with participation from new and existing investors, including Nextech Invest and Euclidean Capital..

此次融资由专栏组牵头，新的和现有的投资者参与，包括Nextech Invest和Euclidean Capital。。

The proceeds from the financing will be used to fund the clinical development of CID-078, Circle Pharma’s first-and-only-in-class cyclin A/B RxL inhibitor, and to support the development of the company’s portfolio of discovery programs built with its MXMO macrocycle platform.

融资所得将用于资助Circle Pharma第一个也是唯一一个同类细胞周期蛋白A/B RxL抑制剂CID-078的临床开发，并支持公司利用其MXMO大环平台构建的发现项目组合的开发。

'We are grateful for the continued support of such a strong syndicate of investors as we advance our pioneering work in macrocycle therapeutics,' said David Earp, JD, Ph.D., CEO of Circle Pharma. 'This financing not only enables us to progress CID-078 through critical stages of clinical development but also allows us to further advance our pipeline of innovative therapies targeting cancer and other serious diseases.'.

Circle Pharma首席执行官、法学博士大卫·厄普（DavidEarp）说，我们非常感谢如此强大的投资者财团的持续支持，因为我们推进了大环治疗的开创性工作这种融资不仅使我们能够在临床开发的关键阶段推进CID-078，而且还使我们能够进一步推进针对癌症和其他严重疾病的创新疗法。”。

With this latest round of funding, Circle Pharma is well positioned to advance its mission of creating effective treatments for cancer and other serious illnesses.

有了这一最新一轮的资金，Circle Pharma完全有能力推进其为癌症和其他严重疾病创造有效治疗方法的使命。

About Circle Pharma, Inc.

关于Circle Pharma，Inc。

South San Francisco-based Circle Pharma is advancing the discovery and development of intrinsically cell-permeable macrocycles that can be delivered by multiple routes, including oral administration. Circle Pharma’s MXMO™ platform combines structure-based rational drug design and advanced synthetic chemistry to develop a new generation of macrocycle therapies for challenging targets to address unmet clinical needs.

总部位于南旧金山的Circle Pharma正在推进本质上可渗透细胞的大环化合物的发现和开发，这些大环化合物可以通过多种途径递送，包括口服给药。Circle Pharma的MXMO™平台结合了基于结构的合理药物设计和先进的合成化学，开发了新一代大环疗法，以应对挑战性目标，以满足未满足的临床需求。

Circle Pharma is focusing its development efforts on cyclins, which are master regulators of the machinery that controls the progression of cells through the cell cycle and are key drivers in many cancers..

Circle Pharma将其开发工作重点放在细胞周期蛋白上，细胞周期蛋白是控制细胞在细胞周期中进展的主要调节因子，也是许多癌症的关键驱动因素。。

To learn more about Circle Pharma, please visit www.circlepharma.com.

欲了解更多有关Circle Pharma的信息，请访问www.circlepharma.com。